Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Barclays PLC

Barclays PLC cut its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 7.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 52,429 shares of the company's stock after selling 4,111 shares during the period. Barclays PLC owned approximately 0.18% of Krystal Biotech worth $8,213,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Norges Bank acquired a new stake in shares of Krystal Biotech in the 4th quarter valued at approximately $34,391,000. Raymond James Financial Inc. purchased a new stake in Krystal Biotech in the 4th quarter worth approximately $15,989,000. Franklin Resources Inc. boosted its holdings in shares of Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after purchasing an additional 62,178 shares during the last quarter. TimesSquare Capital Management LLC increased its stake in Krystal Biotech by 39.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock valued at $24,888,000 after purchasing an additional 44,646 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after buying an additional 28,707 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

Shares of KRYS stock traded down $2.33 on Tuesday, hitting $167.41. 52,514 shares of the stock traded hands, compared to its average volume of 294,653. The company's fifty day moving average is $176.24 and its 200 day moving average is $171.50. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34. The company has a market capitalization of $4.84 billion, a PE ratio of 55.77 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the firm posted $0.30 EPS. The company's revenue for the quarter was up 116.4% on a year-over-year basis. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on KRYS shares. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. HC Wainwright raised their target price on Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a report on Monday. Chardan Capital upped their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and a consensus price target of $222.71.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).